S. Ayanoglou
Thanks, Waqaas.
audited year XXXX. fiscal our the Let's highlights quarter and review of fourth
popularity the the usage-based strong which our Technology-as-a-Service adoption, generated to cellular and revenue particularly driven our cardiac and continue of Biocore demand features devices, our monitoring subscription subscriptions see FDA-cleared model as as recurring well next-generation remains Pro, market Our Bioflux. by from Biocore robust, Both connectivity.
Atrial focus. heartbeats we date, fibrillation, monitored that over providing to has recorded XXX Biotricity opportunities billion remains improving a To outcomes. and strokes estimate a early contributor and significant primary intervention patient
individuals Over the we intervention. improves earlier facilitated that care the estimate we broader over system. health cost of underscores last have patient and X care not XXX,XXX significant them opportunity also atrial fibrillation, health for for only but a patients with savings outcomes years, medical diagnosis providing both the This
XX, For the increased revenue March to by fourth quarter year-over-year XXXX, ended million. XX.X% $X.X
of is a million efficacy a and XX% flat improvement of testament this, $X.XX in the compared higher sales our $XX.XX our the to focus stream. by This million customer a year, For is base though, year. initiatives. our strategic revenue model, the prior which earnings to growth a subscription-based fiscal rose existing the quality new establishes and fee more revenue transitioning to in on significant predictable quality to Underlying
reflecting accounted of for $X.X up strong customer and revenue, quarter's our in from profit totaled the of Gross XX% fees million our $X.X prior quality services. the XX% for quarter period. support over total Technology the million, the retention year
the Our prior ended XXXX, in March for XX.X% was compared as percentage fiscal gross the XX, year year. to profit XX.X%
improvements. AI XX% in significant same of cost These was proprietary margin For year. structure. in increase fourth automation revenue, quarter, margin using are base expansion gained well and the gross in XX.X%, the fee quarter improvement gross operational the monitoring technology was This in as in efficiencies revenue result as from recurring in a up last
of hundreds the of Through our serving centers. across expanded team, we success our to footprint sales continued of geographic thousands states have XX cardiologists
and business market direct our over professionals in-sourcing efficiencies control have enabling model penetration. enhancing services broader Our to cardiac medical allows
year a March the decrease XXXX, $XX.X from the million XX, prior fiscal million, Operating $XX.X in expenses ended were for year.
operating For million the year. in last $X.X fourth were $X same million quarter, to compared the period expenses
expense. on by year $X to we or should Our R&D in expenses full by we It onetime reduced our increase noted largely SG&A XX%, XX%. SG&A decreased a that by XX%. million and was SG&A basis, The expenses reduced be quarterly due a
and have strategically networks GPO on transformed sales longer organizations to group sell independent We purchasing and hospitals. including that's focus our cycles into hospitals larger sales force that accounts,
As to Waqaas networks, access approximately the of U.S. in hospitals the mentioned, X now XX% of largest GPO signed providing we've us
within structure Our future calendar device fees. tech and shift cost our dividends, in sales that has paid subscription impact sales a toward management to path approach, increasing neutrality, with rewarding compensation achieving combined proactive later EBITDA us resulting has positively year. our breakeven new on streamlined EBITDA operations device this sales will set This
implementing our were total in a On an nearly an loss improved $X.X reduced measures. million, basis, operating developing FDA We obtaining resulting building from technology, are effective year-to-date by progress with expenses $X.X pleased registrations, our made force the by and million. sales in operations cost-cutting
the stockholders common was million, fiscal XX, compared year ended to the $XX.X attributable prior March a net to fiscal during XXXX million loss Net $XX.X year. loss for of
from growth, net by $X.X million and fiscal million interest 'XX. increased rising loss quarter, variable expenses fourth QX the decreased year rates. For the $X.X Despite with in infrastructure associated
the towards fiscal Adjusted $X.X from of of EBITDA fiscal progress 'XX. $XX.X profitability. million loss and underscores to year a our in improvement improved breakeven for million This loss a
committed Biocore/Bioflux and Looking to our advancing products. of commercialization Biocare ahead, the remain we
We've made jurisdictions. will These new allow is countries in we for the in on Our world. from useful #X regulatory to us other received approvals entire bodies initiatives of to or XXXX. chronic us sell in inroads that globally. set truly Cardiac the tech recently care move up the that condition is other intend
position. our for The reinforce market growing our dedicated our market products interest in management demand prevention and chronic confidence of to and suite cardiac disease
diagnostic Importantly, post on for in excited about for ability and us to in our sustained focus innovation and closer diagnostic advancements solutions development bringing are products, our deliver to continues the growth and positive to flow. achieving both yield and significant future cash profitability Biotricity. remote monitoring confident We're
that the Operator, our remarks. And questions. please for concludes prepared line open
